Navigation Links
Berg Biosystems and GNS Healthcare Announce Joint Venture - MAP Biosystems
Date:3/2/2011

CAMBRIDGE, Mass., March 2, 2011 /PRNewswire/ -- Berg Biosystems, LLC (Berg) and GNS Healthcare, Inc. (GNS), a subsidiary of Via Science, today announced that they have entered into a joint venture named MAP Biosystems, LLC (MAP) to combine their unique capabilities to accelerate advancements in critical biomedical research.  MAP will utilize a combination of Berg's novel Interrogative Biology drug discovery platform, and GNS's patented supercomputer-driven REFS™ modeling and simulation platform, to unlock the key molecular drivers of complex diseases and drug efficacy and safety.  The joint venture will focus on the repositioning of existing drugs for use in new indications with collaborators. Financial terms of the joint venture were not disclosed.

Dr. Niven R. Narain, President & CTO of Berg, said, "MAP represents to biological investigation a new paradigm of physiological understanding based upon a robust network intelligence of disease.  The unique combination of unbiased systems biology and artificial-intelligence based systems engineering creates a true data driven approach to therapeutic and diagnostic development."

Narain will be speaking on applications of the Berg discovery platform and the GNS Healthcare platform in La Jolla, CA on March 2nd at the AACR-NCI sponsored conference on Systems Biology: Confronting the Complexity of Cancer. The title of the talk is "Inferring causality to unravel the network intelligence of cancer by employing a novel systems biology drug discovery platform."

The combined platforms will allow for insight into biology drawing from "omic-based", pre-clinical, and clinical data feeds employing computational biology methods to create a differential understanding of disease and health.  The collaboration signifies a novel innovative step in medicine that seeks to understand causality and use it as a template for a new generation of drug development.

"MAP has in its arsenal two unparalleled yet complementary technologies – one to generate uniquely deep and broad biological readouts of disease biology and another to readily turn those readouts into knowledge," said Colin C. Hill, CEO and co-founder of GNS Healthcare.  "We are looking forward to unraveling hidden mechanisms of efficacy and toxicity of drugs to rapidly address unmet medical needs using these technologies."

About Berg Biosystems, LLC

Berg Biosystems is a Boston, Massachusetts based company that employs a novel approach to systems biology and utilizes systems engineering and bioinformatic modules to cross-validate biological output. The Berg Interrogative Biology™ Drug Discovery Platform allows for rapid and precise identification of therapeutic and biomarker candidates for drug discovery and development. The company uses network biology templates to mine disease pathophysiology.

About REFS™

REFS™ is comprised of integrated machine learning algorithms and software that extract "causal" relationships from complex, multi-dimensional data and enable the simulation of billions of "what if?" hypotheses to explore novel unseen conditions and predictions forward in time. This model-centric discovery and simulation approach represents a paradigm shift in data analysis, leapfrogging existing approaches such as high-dimensional pattern matching.  REFS™ is licensed to GNS Healthcare from Via Science.

About GNS Healthcare, Inc.

GNS Healthcare, a subsidiary of Via Science, is a healthcare IT company that applies machine learning and simulation technology to optimize patient treatment in partnership with health insurance companies, pharmacy benefit managers, and pharmaceutical and biotechnology companies. GNS Healthcare is the information guru between drug makers and drug buyers matching drugs to patients to deliver on the promise of "smart" medicine.

For more information, contact Thomas A. Neyarapally, 617-494-0492.


'/>"/>
SOURCE GNS Healthcare, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
2. NEXUS Biosystems Acquires Tecan Groups REMP Sample Management Business
3. NEXUS Biosystems Completes Acquisition of REMP Sample Management Business From Tecan Group
4. Biosystems International Merges With Microbiochips
5. Incept BioSystems Completes First Human Clinical Trial of the SMART Start™ Embryo Culture System and Submits 510(k) Application to the FDA
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. ViroPharma to Present at Three Upcoming Healthcare Conferences
9. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
10. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
11. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and ... Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD ... that can be easily incorporated into liquid products, while reducing costs to end users. ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
Breaking Medicine News(10 mins):